Vimarsana
Biggest News Aggregation in the World

Adverse Features News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Adverse Features. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Adverse Features Today - Breaking & Trending Today

Actinium Pharmaceuticals Announces Iomab-B SIERRA Trial Database Lock, Provides Corporate Update Highlighting Key Upcoming Milestones - Vimarsana News

Actinium Pharmaceuticals Announces Iomab-B SIERRA Trial Database Lock, Provides Corporate Update Highlighting Key Upcoming Milestones

Published: September 21, 2022

On track to report topline data from the Pivotal Phase 3 SIERRA trial for Iomab-B in Q4 2022 Overall survival data from the Actimab-A CLAG-M combination trial...

Source: prnewswire.com
Related Topics:
United StatesHans VitzthumSandesh SethActinium Technology PlatformLifesci AdvisorsAlpha Therapy ProgramTechnology PlatformResearch ProgramsDrug AdministrationAmerican Society For TransplantationInternational Blood Marrow Transplant ResearchExchange CommissionActinium Pharmaceuticals IncEuropean Medicines AgencyPrnewswire Actinium Pharmaceuticals IncPivotal PhaseComplete RemissionOverall SurvivalAmerican SocietyCellular TherapyInternational BloodMarrow Transplant ResearchOrphan Drug DesignationAlpha TherapyHigh Rates
Actinium Announces Multiple Abstracts Highlighting Iomab-B and Actimab-A Accepted for Presentation at the 63rd Annual American Society of Hematology Annual Meeting - Vimarsana News

Actinium Announces Multiple Abstracts Highlighting Iomab-B and Actimab-A Accepted for Presentation at the 63rd Annual American Society of Hematology Annual Meeting

Published: November 4, 2021

/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for...

Source: prnewswire.com
Related Topics:
United StatesGeorgia World Congress CenterSandesh SethHans VitzthumLifesci AdvisorsAmerican Society Of HematologyExchange CommissionAstellas Pharma IncActinium Pharmaceuticals IncMemorial Sloan Kettering Cancer CenterPrnewswire Actinium Pharmaceuticals IncAnnual MeetingRandomized PhaseSuccessful EngraftmentAcceptable SafetyNot RespondingConditioning RegimensAcute ToxicitiesAdverse FeaturesInterim ResultsMyeloid LeukemiasInvestigational TherapiesExcluding TransplantationClinical EvaluationPotential Synergy